Literature DB >> 25473174

Hepatitis C infection and lymphoproliferative disease: accidental comorbidities?

Tawfik Khoury1, Shmuel Chen1, Tomer Adar1, E Ollech Jacob1, Meir Mizrahi1.   

Abstract

Chronic hepatitis C virus (HCV) infection has been associated with liver cancer and cirrhosis, autoimmune disorders such as thyroiditis and mixed cryoglobulinema, and alterations in immune function and chronic inflammation, both implicated in B cell lymphoproliferative diseases that may progress to non-Hodgkin lymphoma (NHL). HCV bound to B cell surface receptors can induce lymphoproliferation, leading to DNA mutations and/or lower antigen response thresholds. These findings and epidemiological reports suggest an association between HCV infection and NHL. We performed a systematic review of the literature to clarify this potential relationship. We searched the English-language literature utilizing Medline, Embase, Paper First, Web of Science, Google Scholar, and the Cochrane Database of Systematic Reviews, with search terms broadly defined to capture discussions of HCV and its relationship with NHL and/or lymphoproliferative diseases. References were screened to further identify relevant studies and literature in the basic sciences. A total of 62 reports discussing the relationship between HCV, NHL, and lymphoproliferative diseases were identified. Epidemiological studies suggest that at least a portion of NHL may be etiologically attributable to HCV, particularly in areas with high HCV prevalence. Studies that showed a lack of association between HCV infection and lymphoma may have been influenced by small sample size, short follow-up periods, and database limitations. The association appears strongest with the B-cell lymphomas relative to other lymphoproliferative diseases. Mechanisms by which chronic HCV infection promotes lymphoproliferative disease remains unclear. Lymphomagenesis is a multifactorial process involving genetic, environmental, and infectious factors. HCV most probably have a role in the lymphomagenesis but further study to clarify the association and underlying mechanisms is warranted.

Entities:  

Keywords:  Blood; Hepatitis C infection; Non-Hodgkin’s lymphoma; Pathogenesis; Treatment

Mesh:

Year:  2014        PMID: 25473174      PMCID: PMC4239508          DOI: 10.3748/wjg.v20.i43.16197

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  63 in total

1.  Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma.

Authors:  E Zuckerman; T Zuckerman; A M Levine; D Douer; K Gutekunst; M Mizokami; D G Qian; M Velankar; B N Nathwani; T L Fong
Journal:  Ann Intern Med       Date:  1997-09-15       Impact factor: 25.391

2.  Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection.

Authors:  M Ohsawa; N Shingu; H Miwa; H Yoshihara; M Kubo; H Tsukuma; H Teshima; M Hashimoto; K Aozasa
Journal:  Int J Cancer       Date:  1999-01-18       Impact factor: 7.396

Review 3.  Hepatitis C virus-related lymphomas.

Authors:  F Silvestri; M Baccarani
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

4.  Hepatitis C and B-cell lymphoma.

Authors:  A Kashyap; A Nademanee; A Molina
Journal:  Ann Intern Med       Date:  1998-04-15       Impact factor: 25.391

5.  Hepatitis C infection and risk of malignant lymphoma.

Authors:  Claudia Schöllkopf; Karin Ekström Smedby; Henrik Hjalgrim; Klaus Rostgaard; Inge Panum; Lasse Vinner; Ellen T Chang; Bengt Glimelius; Anna Porwit; Christer Sundström; Mads Hansen; Hans-Olov Adami; Mads Melbye
Journal:  Int J Cancer       Date:  2008-04-15       Impact factor: 7.396

6.  Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.

Authors:  R Misiani; P Bellavita; D Fenili; G Borelli; D Marchesi; M Massazza; G Vendramin; B Comotti; E Tanzi; G Scudeller
Journal:  Ann Intern Med       Date:  1992-10-01       Impact factor: 25.391

7.  Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins.

Authors:  Keigo Machida; Kyoko Tsukiyama-Kohara; Satoshi Sekiguch; Eiji Seike; Shigenobu Tóne; Yukiko Hayashi; Yoshimi Tobita; Yuri Kasama; Masumi Shimizu; Hidemi Takahashi; Chyoji Taya; Hiromichi Yonekawa; Nobuyuki Tanaka; Michinori Kohara
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

8.  Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin.

Authors:  H Meisel; A Reip; B Faltus; M Lu; H Porst; M Wiese; M Roggendorf; D H Krüger
Journal:  Lancet       Date:  1995-05-13       Impact factor: 79.321

9.  Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study.

Authors:  S Franceschi; J Polesel; M Rickenbach; L Dal Maso; N M Probst-Hensch; C Fux; M Cavassini; B Hasse; A Kofler; B Ledergerber; P Erb; G M Clifford
Journal:  Br J Cancer       Date:  2006-11-14       Impact factor: 7.640

10.  Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4.

Authors:  Abdel-Rahman N Zekri; Hanaa M Alam El-Din; Abeer A Bahnassy; Naglaa A Zayed; Waleed S Mohamed; Suzan H El-Masry; Sayed K Gouda; Gamal Esmat
Journal:  Comp Hepatol       Date:  2010-01-05
View more
  4 in total

1.  Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.

Authors:  Megan M Herr; Sara J Schonfeld; Graça M Dores; Eric A Engels; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton
Journal:  Blood Adv       Date:  2019-07-09

Review 2.  Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.

Authors:  Romeo-Gabriel Mihăilă
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

Review 3.  Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.

Authors:  Gabriele Pozzato; Cesare Mazzaro; Luigino Dal Maso; Endri Mauro; Francesca Zorat; Giulia Moratelli; Pietro Bulian; Diego Serraino; Valter Gattei
Journal:  World J Hepatol       Date:  2016-01-18

Review 4.  Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?

Authors:  Chalermrat Bunchorntavakul; Robert Mitrani; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-12-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.